56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy
Abstract Introduction The prognosis of chronic inflammatory diseases has been transformed by the use of biologic drugs. However, there is evidence of an increased risk of infection in patients undergoing biotherapy. The objective of our study was to investigate the frequency and the severity of infe...
Gespeichert in:
Veröffentlicht in: | Rheumatology (Oxford, England) England), 2022-10, Vol.61 (Supplement_2) |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | Supplement_2 |
container_start_page | |
container_title | Rheumatology (Oxford, England) |
container_volume | 61 |
creator | Hiba, Ben Ayed Sarra, Ben Yacoub Manel, Boudokhane Rym, Bourguiba Zeineb, Teyeb Mariem, Ayari Taieb, Jomni Imen, Abdelaali Syrine, Belakhal Hedi, Dougui Mohamed |
description | Abstract
Introduction
The prognosis of chronic inflammatory diseases has been transformed by the use of biologic drugs. However, there is evidence of an increased risk of infection in patients undergoing biotherapy. The objective of our study was to investigate the frequency and the severity of infections in patients on biotherapy.
Methods
We conducted a retrospective descriptive study including all patients followed in the internal medicine department of the ISF hospital and treated with biotherapy over a period of 14 years [2009–2022].
Results
We identified 50 patients treated with biologic therapy among 76 patients. The patient’s mean age was 48 years± 12.5 [23–76] and male to female ratio (M: F) was 1 :6. The mean age at initiation of biotherapy was 41.3 ± 11.6 [17–68] years. The molecules used were TNFα inhibitors in 82% of cases, rituximab in 14% of cases and tocilizumab in 4%. Infectious complications were identified in 20 patients. Infections occurred after a mean duration of 12 months [0.5–36] after the initiation of biotherapy. They affected the skin in nine cases, the bronchopulmonary tract in seven cases, the central nervous system in four cases, the gastrointestinal tract in three cases, and the upper respiratory tract in two cases. The infection was bacterial in 16 cases (64%), viral in five cases (20%) and fungal in four cases (16%). We report five cases of tuberculosis (TB), including four cases of pulmonary TB and one case of neuro-meningeal TB. The infection was severe, requiring hospitalization in only eight cases (32%). The median duration of hospitalization was 12 days [2–58]. The infectious episode led to temporary interruption of biotherapy in six cases and definitive interruption in two cases. No deaths were noted.
Conclusion
Our study confirms the increased susceptibility to infections in patients treated with biologics. These infections, often bacterial, are in the majority of cases benign. However, tuberculosis remains frequent. |
doi_str_mv | 10.1093/rheumatology/keac496.052 |
format | Article |
fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_rheumatology_keac496_052</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/keac496.052</oup_id><sourcerecordid>10.1093/rheumatology/keac496.052</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1432-6eb87c7055ad456caeaee6121f76ec6ff0e978bd245610cd4944cf56c63cbec73</originalsourceid><addsrcrecordid>eNqNkM1KxDAUhYMoOI6-Q16gM_lr2i5l8A8GdKHrkqY3TnSalCQd6U7wTX2SqcwgLl3dA5fvwPkQwpQsKKn4Mmxg6FTyW_86Lt9BaVHJBcnZCZpRIVlGOGenv5mJc3QR4xshJKe8nCGTy-_Pr6cAO7UFpwEr1-IIOwg2jdgbbJ0Bnax3cYq4V8mCSxF_2LTBcYwJOquxGpK3XTc4wK2NoCJE7B1urE8bCKofL9GZUdsIV8c7Ry-3N8-r-2z9ePewul5nmgrOMglNWeiC5LlqRS61AgUgKaOmkKClMQSqomxaNj0p0a2ohNDTBC25bkAXfI7KQ68OPsYApu6D7VQYa0rqH1_1X1_10Vc9-ZpQfkD90P-f2gOUS3oi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Hiba, Ben Ayed ; Sarra, Ben Yacoub ; Manel, Boudokhane ; Rym, Bourguiba ; Zeineb, Teyeb ; Mariem, Ayari ; Taieb, Jomni ; Imen, Abdelaali ; Syrine, Belakhal ; Hedi, Dougui Mohamed</creator><creatorcontrib>Hiba, Ben Ayed ; Sarra, Ben Yacoub ; Manel, Boudokhane ; Rym, Bourguiba ; Zeineb, Teyeb ; Mariem, Ayari ; Taieb, Jomni ; Imen, Abdelaali ; Syrine, Belakhal ; Hedi, Dougui Mohamed</creatorcontrib><description>Abstract
Introduction
The prognosis of chronic inflammatory diseases has been transformed by the use of biologic drugs. However, there is evidence of an increased risk of infection in patients undergoing biotherapy. The objective of our study was to investigate the frequency and the severity of infections in patients on biotherapy.
Methods
We conducted a retrospective descriptive study including all patients followed in the internal medicine department of the ISF hospital and treated with biotherapy over a period of 14 years [2009–2022].
Results
We identified 50 patients treated with biologic therapy among 76 patients. The patient’s mean age was 48 years± 12.5 [23–76] and male to female ratio (M: F) was 1 :6. The mean age at initiation of biotherapy was 41.3 ± 11.6 [17–68] years. The molecules used were TNFα inhibitors in 82% of cases, rituximab in 14% of cases and tocilizumab in 4%. Infectious complications were identified in 20 patients. Infections occurred after a mean duration of 12 months [0.5–36] after the initiation of biotherapy. They affected the skin in nine cases, the bronchopulmonary tract in seven cases, the central nervous system in four cases, the gastrointestinal tract in three cases, and the upper respiratory tract in two cases. The infection was bacterial in 16 cases (64%), viral in five cases (20%) and fungal in four cases (16%). We report five cases of tuberculosis (TB), including four cases of pulmonary TB and one case of neuro-meningeal TB. The infection was severe, requiring hospitalization in only eight cases (32%). The median duration of hospitalization was 12 days [2–58]. The infectious episode led to temporary interruption of biotherapy in six cases and definitive interruption in two cases. No deaths were noted.
Conclusion
Our study confirms the increased susceptibility to infections in patients treated with biologics. These infections, often bacterial, are in the majority of cases benign. However, tuberculosis remains frequent.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keac496.052</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Rheumatology (Oxford, England), 2022-10, Vol.61 (Supplement_2)</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids></links><search><creatorcontrib>Hiba, Ben Ayed</creatorcontrib><creatorcontrib>Sarra, Ben Yacoub</creatorcontrib><creatorcontrib>Manel, Boudokhane</creatorcontrib><creatorcontrib>Rym, Bourguiba</creatorcontrib><creatorcontrib>Zeineb, Teyeb</creatorcontrib><creatorcontrib>Mariem, Ayari</creatorcontrib><creatorcontrib>Taieb, Jomni</creatorcontrib><creatorcontrib>Imen, Abdelaali</creatorcontrib><creatorcontrib>Syrine, Belakhal</creatorcontrib><creatorcontrib>Hedi, Dougui Mohamed</creatorcontrib><title>56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy</title><title>Rheumatology (Oxford, England)</title><description>Abstract
Introduction
The prognosis of chronic inflammatory diseases has been transformed by the use of biologic drugs. However, there is evidence of an increased risk of infection in patients undergoing biotherapy. The objective of our study was to investigate the frequency and the severity of infections in patients on biotherapy.
Methods
We conducted a retrospective descriptive study including all patients followed in the internal medicine department of the ISF hospital and treated with biotherapy over a period of 14 years [2009–2022].
Results
We identified 50 patients treated with biologic therapy among 76 patients. The patient’s mean age was 48 years± 12.5 [23–76] and male to female ratio (M: F) was 1 :6. The mean age at initiation of biotherapy was 41.3 ± 11.6 [17–68] years. The molecules used were TNFα inhibitors in 82% of cases, rituximab in 14% of cases and tocilizumab in 4%. Infectious complications were identified in 20 patients. Infections occurred after a mean duration of 12 months [0.5–36] after the initiation of biotherapy. They affected the skin in nine cases, the bronchopulmonary tract in seven cases, the central nervous system in four cases, the gastrointestinal tract in three cases, and the upper respiratory tract in two cases. The infection was bacterial in 16 cases (64%), viral in five cases (20%) and fungal in four cases (16%). We report five cases of tuberculosis (TB), including four cases of pulmonary TB and one case of neuro-meningeal TB. The infection was severe, requiring hospitalization in only eight cases (32%). The median duration of hospitalization was 12 days [2–58]. The infectious episode led to temporary interruption of biotherapy in six cases and definitive interruption in two cases. No deaths were noted.
Conclusion
Our study confirms the increased susceptibility to infections in patients treated with biologics. These infections, often bacterial, are in the majority of cases benign. However, tuberculosis remains frequent.</description><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqNkM1KxDAUhYMoOI6-Q16gM_lr2i5l8A8GdKHrkqY3TnSalCQd6U7wTX2SqcwgLl3dA5fvwPkQwpQsKKn4Mmxg6FTyW_86Lt9BaVHJBcnZCZpRIVlGOGenv5mJc3QR4xshJKe8nCGTy-_Pr6cAO7UFpwEr1-IIOwg2jdgbbJ0Bnax3cYq4V8mCSxF_2LTBcYwJOquxGpK3XTc4wK2NoCJE7B1urE8bCKofL9GZUdsIV8c7Ry-3N8-r-2z9ePewul5nmgrOMglNWeiC5LlqRS61AgUgKaOmkKClMQSqomxaNj0p0a2ohNDTBC25bkAXfI7KQ68OPsYApu6D7VQYa0rqH1_1X1_10Vc9-ZpQfkD90P-f2gOUS3oi</recordid><startdate>20221006</startdate><enddate>20221006</enddate><creator>Hiba, Ben Ayed</creator><creator>Sarra, Ben Yacoub</creator><creator>Manel, Boudokhane</creator><creator>Rym, Bourguiba</creator><creator>Zeineb, Teyeb</creator><creator>Mariem, Ayari</creator><creator>Taieb, Jomni</creator><creator>Imen, Abdelaali</creator><creator>Syrine, Belakhal</creator><creator>Hedi, Dougui Mohamed</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221006</creationdate><title>56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy</title><author>Hiba, Ben Ayed ; Sarra, Ben Yacoub ; Manel, Boudokhane ; Rym, Bourguiba ; Zeineb, Teyeb ; Mariem, Ayari ; Taieb, Jomni ; Imen, Abdelaali ; Syrine, Belakhal ; Hedi, Dougui Mohamed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1432-6eb87c7055ad456caeaee6121f76ec6ff0e978bd245610cd4944cf56c63cbec73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hiba, Ben Ayed</creatorcontrib><creatorcontrib>Sarra, Ben Yacoub</creatorcontrib><creatorcontrib>Manel, Boudokhane</creatorcontrib><creatorcontrib>Rym, Bourguiba</creatorcontrib><creatorcontrib>Zeineb, Teyeb</creatorcontrib><creatorcontrib>Mariem, Ayari</creatorcontrib><creatorcontrib>Taieb, Jomni</creatorcontrib><creatorcontrib>Imen, Abdelaali</creatorcontrib><creatorcontrib>Syrine, Belakhal</creatorcontrib><creatorcontrib>Hedi, Dougui Mohamed</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>CrossRef</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hiba, Ben Ayed</au><au>Sarra, Ben Yacoub</au><au>Manel, Boudokhane</au><au>Rym, Bourguiba</au><au>Zeineb, Teyeb</au><au>Mariem, Ayari</au><au>Taieb, Jomni</au><au>Imen, Abdelaali</au><au>Syrine, Belakhal</au><au>Hedi, Dougui Mohamed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><date>2022-10-06</date><risdate>2022</risdate><volume>61</volume><issue>Supplement_2</issue><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>Abstract
Introduction
The prognosis of chronic inflammatory diseases has been transformed by the use of biologic drugs. However, there is evidence of an increased risk of infection in patients undergoing biotherapy. The objective of our study was to investigate the frequency and the severity of infections in patients on biotherapy.
Methods
We conducted a retrospective descriptive study including all patients followed in the internal medicine department of the ISF hospital and treated with biotherapy over a period of 14 years [2009–2022].
Results
We identified 50 patients treated with biologic therapy among 76 patients. The patient’s mean age was 48 years± 12.5 [23–76] and male to female ratio (M: F) was 1 :6. The mean age at initiation of biotherapy was 41.3 ± 11.6 [17–68] years. The molecules used were TNFα inhibitors in 82% of cases, rituximab in 14% of cases and tocilizumab in 4%. Infectious complications were identified in 20 patients. Infections occurred after a mean duration of 12 months [0.5–36] after the initiation of biotherapy. They affected the skin in nine cases, the bronchopulmonary tract in seven cases, the central nervous system in four cases, the gastrointestinal tract in three cases, and the upper respiratory tract in two cases. The infection was bacterial in 16 cases (64%), viral in five cases (20%) and fungal in four cases (16%). We report five cases of tuberculosis (TB), including four cases of pulmonary TB and one case of neuro-meningeal TB. The infection was severe, requiring hospitalization in only eight cases (32%). The median duration of hospitalization was 12 days [2–58]. The infectious episode led to temporary interruption of biotherapy in six cases and definitive interruption in two cases. No deaths were noted.
Conclusion
Our study confirms the increased susceptibility to infections in patients treated with biologics. These infections, often bacterial, are in the majority of cases benign. However, tuberculosis remains frequent.</abstract><pub>Oxford University Press</pub><doi>10.1093/rheumatology/keac496.052</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1462-0324 |
ispartof | Rheumatology (Oxford, England), 2022-10, Vol.61 (Supplement_2) |
issn | 1462-0324 1462-0332 |
language | eng |
recordid | cdi_crossref_primary_10_1093_rheumatology_keac496_052 |
source | Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
title | 56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T08%3A19%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=56%E2%80%83Prevalence%20and%20severity%20of%20infections%20in%20patients%20with%20systemic%20autoimmune%20diseases%20on%20biotherapy&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Hiba,%20Ben%20Ayed&rft.date=2022-10-06&rft.volume=61&rft.issue=Supplement_2&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keac496.052&rft_dat=%3Coup_cross%3E10.1093/rheumatology/keac496.052%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/rheumatology/keac496.052&rfr_iscdi=true |